Despite the central role of the liver in the regulation of glucose and lipid metabolism, there are currently no methods to directly assess hepatic oxidative metabolism in humans in vivo. By using a new 13 C-labeling strategy in combination with 13 C magnetic resonance spectroscopy, we show that rates of mitochondrial oxidation and anaplerosis in human liver can be directly determined noninvasively. Using this approach, we found the mean rates of hepatic tricarboxylic acid (TCA) cycle flux (V TCA ) and anaplerotic flux (V ANA ) to be 0.43 6 0.04 mmol g −1 min −1 and 0.60 6 0.11 mmol g −1 min −1 , respectively, in twelve healthy, lean individuals. We also found the V ANA /V TCA ratio to be 1.39 6 0.22, which is severalfold lower than recently published estimates using an indirect approach. This method will be useful for understanding the pathogenesis of nonalcoholic fatty liver disease and type 2 diabetes, as well as for assessing the effectiveness of new therapies targeting these pathways in humans.
Despite the central role of the liver in the regulation of glucose and lipid metabolism, there are currently no methods to directly assess hepatic oxidative metabolism in humans in vivo. By using a new 13 C-labeling strategy in combination with 13 C magnetic resonance spectroscopy, we show that rates of mitochondrial oxidation and anaplerosis in human liver can be directly determined noninvasively. Using this approach, we found the mean rates of hepatic tricarboxylic acid (TCA) cycle flux (V TCA ) and anaplerotic flux (V ANA ) to be 0.43 6 0.04 mmol g −1 min −1 and 0.60 6 0.11 mmol g −1 min −1 , respectively, in twelve healthy, lean individuals. We also found the V ANA /V TCA ratio to be 1.39 6 0.22, which is severalfold lower than recently published estimates using an indirect approach. This method will be useful for understanding the pathogenesis of nonalcoholic fatty liver disease and type 2 diabetes, as well as for assessing the effectiveness of new therapies targeting these pathways in humans.
The liver plays a central part in the regulation of normal glucose and lipid homeostasis and in the pathogenesis of type 2 diabetes. Both hepatic mitochondrial V TCA and V ANA are critical functions in this regard given their major roles in hepatic fatty acid oxidation and gluconeogenesis. However, despite their importance, there are currently no methods to directly assess these fluxes in human liver. Indirect estimates of hepatic fluxes in humans have been obtained recently by examining the isotopomer-labeling patterns of plasma glucose using a multiple-tracer method in combination with ex vivo analysis by 13 C and 2 H nuclear magnetic resonance (NMR) 1-3 , a method derived from techniques originally developed using radioactive tracers 4, 5 . The relative rate of hepatic anaplerosis to TCA cycle flux was determined from the 13 C isotopomers of the C 2 carbon of plasma glucose following the ingestion of [U- 13 C] propionate (propionate uniformly labeled with 13 C); using this technique, the V ANA /V TCA ratio was found to be approximately 5 (ref. 3) . Absolute anaplerotic and TCA cycle fluxes were then calculated from measurements of whole-body glucose turnover combined with rates of gluconeogenesis determined by deuterium labeling of glucose at C2 and C5 from ingested 2 H water. However, this approach assesses rates of anaplerosis and TCA cycle flux indirectly, and the fluxes are necessarily expressed in terms of body weight or lean body mass rather than per amount of liver tissue, which complicates interpretation of the data when comparing results among subjects with differing body compositions and body weights.
In contrast, in vivo magnetic resonance spectroscopy (MRS) offers the major advantage of being able to directly assess rates of intracellular metabolism in an organ-specific manner [6] [7] [8] [9] [10] [11] . Hepatic energetics have been investigated in patients with type 2 diabetes using 31 P MRS techniques. Szendroedi et al. 12 observed that the concentrations of ATP and inorganic phosphate (P i ) were decreased in the liver of overweight individuals with type 2 diabetes and correlated inversely with hepatic insulin sensitivity. This group has also observed that the rate of hepatic ATP turnover (unidirectional P i to ATP flux, assessed by 31 P-saturation-transfer MRS) was decreased in a similar cohort of overweight patients with type 2 diabetes 13 , suggesting that hepatic mitochondrial metabolism may be compromised in type 2 diabetes. Although novel, the 31 P-saturation-transfer-MRS approach does not directly assess hepatic mitochondrial oxidative function 14 . Studies using 13 C MRS have employed [2-13 C]acetate infusions to directly assess mitochondrial oxidative function in skeletal muscle 7, 8, 11, 15 and in glial cells in brain 16, 17 by monitoring the rate of 13 C-label incorporation into glutamate at C4. However, this 13 C-labeling scheme is unsuitable for liver, where the presence of substantial quantities of intracellular lipid obscures the detection of [4-13 C]glutamate. To circumvent this problem, we implemented a new 13 C-labeling strategy, infusing [1-13 C]acetate and monitoring 13 C-label incorporation into liver glutamate at C5 and C1, which, given their chemical shifts, we reasoned would be clear of interfering lipid resonances in vivo [18] [19] [20] .
Using this approach, we show that 13 C enrichment of glutamate at C5 and C1 can be directly detected in human liver without interference from intrahepatic lipid peaks and demonstrate that these data, in turn, can be used to directly assess the absolute fluxes of hepatic V TCA and V ANA . We also validated assumptions underlying the MRS methodology and modeling analysis using analogous experiments in rat liver ex vivo. The successful development of this 13 C MRS technique has yielded, to our knowledge, the first direct measurements of hepatic mitochondrial oxidative and anaplerotic rates in humans and will enhance the investigation of hepatic metabolism in normal humans and those with diabetes, as well as the etiology and treatment of nonalcoholic fatty liver disease (NAFLD).
RESULTS
We recruited twelve young, lean, healthy participants from the local New Haven, Connecticut, community for these studies (see Online Methods). Subjects were screened to eliminate factors that would alter normal hepatic metabolism; all had a normal birth weight and no history of chronic metabolic diseases, were nonsmokers and were not taking any medications. Body mass index for this cohort (22.8 ± 2.0 kg m −2 ) was within the normal range. All subjects had normal (<5.5%) levels of liver triglyceride content assessed by 1 Table 1 ). 13 C MRS assessment of hepatic TCA cycle flux During the infusion study, the plasma acetate concentration and 13 C enrichment were elevated within 5 min after commencing the infusion of [1-13 C]acetate and plateaued by 20 min. There were no significant differences in plasma acetate kinetics with or without a priming dose of [1-13 C]acetate, and results were combined ( Fig. 1) . We performed localized 13 C MRS of the liver ( Fig. 2a ) throughout the infusion protocol, and we observed 13 C labeling of the hepatic glutamate and bicarbonate pools ( Fig. 2b) due to the oxidation of [1-13 C]acetate via the TCA cycle. Enrichment of these metabolites could be detected without interference from the lipid carboxyl group peak at ~172.5 p.p.m. Using this labeling strategy, initial entry of [ 13 C]acetate into the TCA cycle results in enrichment of glutamate at C5, followed by labeling of glutamate at C1 as the 13 C label traverses a second turn of the cycle. The bicarbonate pool also becomes enriched owing to the loss of 13 C-labeled carbon dioxide (CO 2 ) during the decarboxylation reactions of several TCA cycle intermediates, as well as exchange with the plasma CO 2 and bicarbonate pools. A more detailed description of the 13 C-labeling scheme can be found in the Online Methods. 13 C enrichment of glutamate at C5 was detected during the initial 10 min of the [1-13 C]acetate infusion and rapidly attained steady state ( Fig. 3) . 13 C labeling of glutamate at C1 occurred more slowly but also plateaued by the end of the 120-min infusion protocol. We measured hepatic glutamate concentration (5.79 ± 0.38 µmol g −1 , n = 12) by localized, natural-abundance 13 C MRS on a separate occasion.
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Metabolic modeling
Glutamate C5 and C1 13 C enrichment profiles for each subject were fitted to a model of liver oxidative metabolism ( Fig. 4) . We adapted this model from previous schemes used to simulate acetate metabolism in muscle and brain 8, 17, 21 and incorporated modifications to reflect the specific biochemical pathways of hepatic metabolism. These included (i) anaplerotic fluxes to account for the entry of metabolites into the TCA cycle and (ii) gluconeogenesis from TCA cycle intermediates via phosphoenolpyruvate. The modeling scheme is described in detail in the Online Methods.
For each subject, we determined the precision in the rates of hepatic metabolism estimated by the modeling analysis by performing 500 Monte Carlo simulations of the data set followed by probability distribution analysis. Representative data for the estimates of TCA cycle flux and anaplerosis are shown for one of the subjects in Supplementary  Figure 1 . For this group of lean, healthy subjects, the mean rates of hepatic V TCA and V ANA were 0.43 ± 0.04 µmol g −1 min −1 and 0.60 ± 0.11 µmol g −1 min −1 , respectively; the V ANA /V TCA ratio was 1.39 ± 0.22 ( Table 1 and Supplementary Fig. 2 ).
Methodological validation: animal experiments
To validate this methodology, we performed analogous infusion experiments in adult male rats (see Supplementary Methods). 
Figure 2
In vivo 13 C MRS of the human liver. (a) Axial gradient-echo image of the torso acquired during a single breath hold. 1 H-decoupled 13 C magnetic resonance spectra were acquired from a localized region within the liver. Voxel selection was accomplished using outer volume suppression (shaded regions) applied in three dimensions to suppress signals arising from outside the liver and define the volume of interest (white box). (b) Localized 13 C spectra of the human liver acquired before and at the end of a 120-min infusion of [1-13 C]acetate. 13 C labeling at the C5 position of glutamate (C5-Glu) was observed due to the oxidation of [1-13 C]acetate via the TCA cycle. Labeling at glutamate C1 (C1-Glu) and of the bicarbonate (HCO 3 − ) pool was also observed as the 13 C label traversed a second turn of the TCA cycle. 
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DISCUSSION
In this study, we have developed and applied a new 13 C-MRS method to directly assess rates of hepatic oxidative and anaplerotic flux in human liver in vivo. We accomplished this by using a 13 C-labeling scheme that enriches the carboxyl groups of liver glutamate and avoids the interfering resonances of intrahepatic lipid. We detected time courses of 13 C enrichment of hepatic glutamate with sufficient sensitivity and time resolution to permit modeling of the data to yield rates of hepatic V TCA and V ANA in humans. To ensure accurate simulation of the kinetics of 13 C-label turnover, we developed a sophisticated metabolic model of liver oxidative metabolism for these analyses.
Using this approach, we found that the mean rates of hepatic V TCA and V ANA were 0.43 ± 0.04 µmol g −1 min −1 and 0.60 ± 0.11 µmol g −1 min −1 , respectively, yielding a V ANA /V TCA ratio of 1.39 ± 0.22. Our estimate of the V ANA /V TCA ratio in humans is over 300% lower than has been recently been published by Sunny et al. 3 . By assessing the isotopomer splitting pattern in plasma glucose at C2 from ingested [U-13 C]propionate, they found rates of V ANA to be approximately five times greater than V TCA in normal subjects 3 . Such high rates of anaplerosis are incompatible with the extent of 13 C labeling of glutamate at C1 that we have observed in the present study in human liver following an infusion of [1-13 C]acetate. We believe that this discrepancy in V ANA /V TCA may be due to important limitations regarding the use of [U-13 C]propionate as a tracer for assessing hepatic metabolism in vivo. Specifically, propionate enters the TCA cycle as an anaplerotic substrate via succinyl coenzyme A (CoA), which requires obligate utilization via gluconeogenesis and/or pyruvate recycling. Furthermore, Puchowicz et al. 23 have demonstrated that, in contrast to acetate or lactate, very large differences in the gradients for propionate uptake are established between the periportal and perivenous regions of the liver. To examine these issues, we measured glucose turnover in rats infused with low and high doses of [U- 13 C] proprionate within the range used by previous studies 2, 24, 25 . We found that a high dose of exogenous propionate increased plasma glucose concentrations and was associated with an ~30% increase in rates of hepatic glucose production compared to those seen with the low-dose infusions. 
Unlabeled fatty acids We determined positional enrichment of liver glutamate at multiple time points ex vivo by 13 C NMR and liquid chromatography-tandem mass spectrometry of the extracted tissue. We constructed profiles of 13 C glutamate enrichment from the individual time points and fitted this composite data set using our model of hepatic acetate metabolism.
Using this approach, we found that the liver V TCA was approximately 1.2 µmol g −1 min −1 , which is comparable to V TCA rates determined by Beylot et al. 22 in rats in vivo and in perfused livers. We also estimated hepatic V TCA flux rates in these animals indirectly by an independent method wherein we measured the V ANA /V TCA ratio through steady-state labeling of glutamate at C2, C3 and C4 during an infusion of [3-13 C]lactate ( Supplementary Table 2 ) and multiplied this fraction by rates of hepatic gluconeogenesis. This was calculated from endogenous glucose production, assessed by [3-3 H]glucose turnover assuming a 90% contribution from the liver, and from the contribution of pyruvate to gluconeogenesis, which was determined during the infusion of [3-13 C]lactate (see Supplementary Methods).
Using this independent method, we estimated TCA cycle flux to be 1.4 ± 0.4 µmol g −1 min −1 (Supplementary Table 2) , which is in agreement with the rate of V TCA derived using the dynamic metabolic modeling approach.
To investigate the effects of exogenous propionate on hepatic metabolism, we measured glucose turnover in a group of rats infused intravenously with low (333 µmol per kg body weight) and high (666 µmol per kg body weight) doses of [U-13 C]propionate. Plasma glucose concentrations during the high-dose propionate infusions were increased by ~2 5 mg dl −1 over those observed with the lowdose propionate infusions, accompanied by an ~3 0% increase in rates of hepatic glucose production (Supplementary Fig. 3) . In contrast, doubling the infusion rates of [1-13 C]acetate or [3-13 C]lactate had no effects on glucose production, the ratio of pyruvate carboxylase flux (V PC ) to V TCA or the ratio of pyruvate dehydrogenase flux (V PDH ) to V TCA (Supplementary Fig. 3 ). 13 C]propionate at doses in the range used to assess rates of mitochondrial metabolism can alter rates of anaplerosis, making it unsuitable as a tracer for hepatic metabolism. These substrate-driven effects of [U-13 C]propionate on V ANA will probably be further exaggerated when the isotope is given orally, as first-pass portal vein delivery is likely to result in much higher concentrations of propionate being presented to the periportal hepatocytes than when it is administered systemically. Furthermore, in contrast to the in vivo MRS method described here, the [U-13 C]propionate isotope method assumes negligible flux through hepatic pyruvate dehydrogenase, which is not likely to be the case in normal liver ( Supplementary Table 2 ) 26 and does not account for the effects of 13 C-label recycling via CO 2 , which modulates the observed labeling patterns 27 . The methodology described here uses a dynamic approach to monitor metabolite kinetics and estimate metabolic rates. Although the MRS techniques involved in data acquisition are technically demanding, and the metabolic modeling analyses require high-quality data collected over an extended duration (90-120 min of infusion are required to obtain sufficient time points to establish the kinetics of glutamate enrichment), the technique provides reliable, direct estimates of hepatic oxidative metabolism. Relatively modest increments in plasma acetate concentrations are observed (up to ~1 mM), minimizing the likelihood that the provision of exogenous substrate will perturb metabolism in the liver or other organs. Metabolite enrichment in the target tissue is directly assessed, avoiding assumptions about the contributions of other tissues such as the kidney, which may affect whole-body techniques. Additionally, the dynamic approach does not inherently require isotopic steady-state conditions for either the substrate precursor or the target metabolite; however, as both the peripheral circulation and the liver were repeatedly sampled, isotopic steady state was confirmed for these studies.
We also performed a Monte Carlo simulation for each data set, combined with probability distribution analysis to determine the precision with which the metabolic model fitted the in vivo data. This analysis, which determined uncertainty based on spectral noise and deviation of the data from the best fit, showed that reliable estimates of hepatic metabolism were obtained on each of the subjects in this study. It further demonstrates that this method can be used to track hepatic metabolism in individual subjects, opening the possibility of monitoring the impact of interventions that may perturb the liver. The estimated fluxes are sensitive to assumptions underlying the model of hepatic metabolism; therefore, actual error may exceed the estimates reported.
In summary, the use of traditional 13 C-MRS techniques to measure tissue-specific rates of mitochondrial V TCA is not possible in liver owing to the presence of dominant intrahepatic lipid peaks that obscure the detection of conventional 13 C-labeling schemes. By using an innovative labeling strategy, in combination with localized in vivo 13 C MRS, we have directly observed rates of mitochondrial oxidation and anaplerosis in human liver. A sophisticated metabolic model of hepatic metabolism was developed to simulate the kinetics of 13 Clabel turnover, which generated estimates of liver oxidative fluxes. This method will be useful for understanding the potential role of altered hepatic mitochondrial fat oxidation in the pathogenesis of NAFLD and type 2 diabetes, as well as for assessing the effectiveness of new therapies aimed at increasing rates of hepatic fatty oxidation in humans to reverse NAFLD.
METhODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METhODS
Human subjects. All procedures were approved by the Yale University Human Investigation Committee; written informed consent was obtained from each participant after explanation of the purpose, nature and potential complications of the study. Twelve young, lean, healthy volunteers (ten male, two female) were recruited from the local community and were prescreened to be in good health, lean, nonsmokers and taking no medications. Subjects were also selected to have normal levels of intrahepatic lipid content, determined using 1 H MRS.
In vivo 13 C magnetic resonance spectroscopy: general procedure. Studies were performed on a 4.0 Tesla Bruker Medspec system using a custom-built 13 C-1 H probe consisting of a 9-cm-diameter 13 C surface coil with a pair of elliptical 14.5 × 11 cm 1 H coils arrayed in quadrature for imaging, shimming and decoupling. Subjects were positioned supine with the probe attached to a rigid support to minimize extraneous movement. The 13 C-1 H probe was curved in design to site the radiofrequency coils in an optimal position over the lateral aspect of the liver. Scout images of the torso were acquired during an end-expiration breath hold to confirm correct positioning of the probe and to define a volume for localized 13 C spectroscopy. Field homogeneity was optimized using a respiratory-gated FASTMAP routine 28 . 1 H linewidths from an 8-cm 3 volume within the region of interest, acquired using a respiratory-gated stimulated echo-acquisition mode (STEAM) sequence, were typically ~25 Hz. Each participant underwent two MRS sessions typically separated by less than 8 d: a natural abundance 13 C scan to determine the hepatic concentration of glutamate and an infusion study to assess hepatic TCA cycle flux. The localized natural-abundance measurement was performed before the infusion study for 8 of the 12 participants; for the remaining individuals, there was a sufficient interval after the infusion study to ensure full washout of 13 C label before the natural abundance scan. 13 C-magnetic resonance spectroscopy assessment of hepatic glutamate concentrations. Localized 13 C spectra were acquired using a custom-written adiabatic pulse-acquire sequence with WALTZ16 decoupling and threedimensional outer volume suppression to minimize signal arising from the chest wall and select a region of interest within the liver (Fig. 2) . The size of the localized volume varied from subject to subject depending on the morphology of the liver but was typically ~225 cm 3 . Owing to the relatively long T1 relaxation times of the carboxyl groups, spectra were acquired with a repetition time (T R ) of 10 s in blocks of 32 transients and repeated until sufficient signal had been acquired to detect the natural abundance glutamate signal (typically 50-60 min). The hepatic concentration of glutamate was determined from the in vivo glutamate C5 signal relative to the fully relaxed (T R = 30 s) signal obtained from a 25-mM glutamate phantom, using a voxel of identical size and location, after correction for coil loading effects. 13 C-magnetic resonance spectroscopy assessment of hepatic tricarboxylic acid cycle flux. Following an overnight fast, intravenous catheters were inserted into an antecubital vein in each arm. Localized 13 C spectra were obtained over a 20-min baseline period and throughout a 120-min infusion of [1-13 C]acetate (99% enriched, 350 mmol L −1 sodium salt). Subjects underwent either a continuous acetate infusion protocol (n = 6) at a rate of 3.0 mg per kg body weight per min, or a primed-continuous infusion protocol (n = 6), with a 5-min priming dose at 150% of the continuous acetate infusion rate. Spectra were acquired as described above but with nuclear Overhauser enhancement (nOe) applied during the T R (1 ms hard-pulse every 50 ms) to increase 13 C sensitivity. Blood samples were obtained at regular intervals throughout the infusion protocol for the measurement of plasma acetate concentration and 1-13 C fractional enrichment by high-field 1 H NMR at 500 MHz or by gas chromatography-mass spectrometry 21 . To enhance the signal-to-noise ratio, data acquired during the infusion were summed using a four-spectrum rolling average; difference spectra were created for each time point by subtracting the baseline spectrum. Glutamate enrichment at the C5 and C1 positions was determined from each difference spectrum relative to the baseline bicarbonate signal, which was assumed to be 1.1% enriched (i.e., natural abundance for 13 C). Slight differences in nOe for bicarbonate and glutamate C5 in liver and the detection efficiency of glutamate C1 compared with C5 using this pulse sequence were accounted for by means of correction factors determined in vivo and from a glutamate phantom experiment, respectively.
Metabolic modeling. The time courses of hepatic glutamate enrichment for each subject were fitted to a metabolic model of the TCA cycle ( Fig. 4) using CWave software (developed by G. Mason, Yale University). This model consists of a series of isotopic and mass balance differential equations that describe the hepatic metabolism of acetate (see Supplementary Methods) . This model was developed from previous schemes used to examine acetate metabolism in muscle 21 and brain 8, 17, 29 modified to account for liver-specific phenomena, including gluconeogenesis from TCA cycle intermediates via phosphoenolpyruvate, the entry of metabolites into the TCA cycle via anaplerosis and 13 CO 2 recycling.
Acetate uptake occurs via the monocarboxylate transporter; under the systemic acetate concentrations in these studies (~1 mM), acetate transport is assumed to be saturated, and [1-13 C] acetate is converted to [1-13 C] acetyl-CoA within the hepatocyte at the rate V AC . [1-13 C] Acetyl-CoA enters the TCA cycle labeling citrate and α-ketoglutarate at the C5 position. Entry of unlabeled substrates derived from fatty acids or pyruvate is accounted for by the flux V DIL , which dilutes the enrichment of acetyl-CoA. Glutamate and α-ketoglutarate are in rapid exchange (V X ) via asparate aminotransferase, and equilibration results in the 13 C enrichment of glutamate at C5, which can be detected by 13 30 and/or that the PK+ME flux is relatively low [31] [32] [33] . Therefore, only unlabeled pyruvate and 13 CO 2 may enter the TCA cycle via V PC . V ANA is treated as a parameter that is equivalent to V PC and V PEPCK . Backwards scrambling of 13 C label between C1 and C4 of oxaloacetate, due to the action of fumarase, is treated as a simple rapid interconversion between the two species (V FUM ).
Target functions of glutamate C5 and C1 enrichment during the [1-13 C]acetate infusion were created for each subject as described above. The hepatic concentration of glutamate was estimated from a localized, naturalabundance 13 C-MRS measurement. Owing to the high activity of carbonic anhydrase, liver bicarbonate enrichment estimated from the in vivo 13 C spectra was used as a surrogate for the 13 CO 2 input function. The liver bicarbonate concentration was calculated to be 12 mM on the basis of an assumed plasma bicarbonate concentration of 24 mM and a pH difference of 0.3 between liver and blood. Concentrations of the other hepatic metabolic intermediates were estimated from the literature, using average values scaled to the estimated concentration of glutamate for each subject. Owing to the low concentrations npg of these intermediates relative to glutamate, labeling of these metabolites has a negligible impact on the kinetics of glutamate enrichment or the modeled rates of hepatic metabolism. The parameters V AC , V DIL , V TCA and V ANA were estimated by numerical simulation of the differential equations that contribute to the metabolic model. On the basis of previous studies, V X was assumed to be substantially faster than V TCA and nonlimiting. Each simulated parameter was constrained to be greater than or equal to zero. 1 H-magnetic resonance spectroscopy assessment of intrahepatic lipid content. To assess liver lipid content, localized 1 H spectra were obtained from a (15 × 15 × 15)-mm 3 voxel placed in three different locations of the liver. Spectra were acquired using a respiratory-gated stimulated echo-acquisition mode (STEAM) sequence, with chemical-shift-selective peak suppression. Total intrahepatic lipid content was estimated from comparison of a watersuppressed lipid spectrum and a lipid-suppressed water spectrum, with the appropriate peak for each spectrum on-resonance.
Statistical analyses. Data are expressed as mean ± s.e.m. The precision in the fit of the metabolic model to the raw data was determined by probability distribution analysis of 500 Monte Carlo simulations of the model with random Gaussian noise added to the fitted time courses. Probability distribution analysis was performed for each rate parameter on the resultant Monte Carlo data set using the distribution fitting function (dfittool) in Matlab.
